Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2006

View Archived Issues

BYK-191023: new selective iNOS inhibitor and candidate for inflammatory hypotension

Meta-analysis indicates beneficial effects of Chinese herbal medicine for NSCLC

Recent patents describe novel analgesic agents

A new role for Cdk5 in pain signaling

Enrollment ahead of schedule in Onconase phase IIIb study

AVI signs HCV license agreement with Chiron

Daiichi reports new agents for treating allergic disorders

Novel ophthalmic compounds described by Alcon in a recent patent

Recent patents disclose novel agents for cardiovascular disorders

PKC-412 and AMN-107 show promise in systemic mastocytosis with mutated KIT

MediGene and Bradley sign agreement for Polyphenon E Ointment

Pharmion and MethylGene sign agreement for oncology oral HDAC inhibitors

Synergistic activity seen with FK-228 and bortezomib in leukemic cells

AOD-9604 shows potential for osteoporosis

Ferring and Astellas sign licensing agreement for degarelix in Japan

BTG acquires rights to Asterand's pain compounds

Orphan drug designation for TheraQuest's high-concentration capsaicin

Benitec delays IND filing for HIV/AIDS therapeutic

SNS-032 begins phase I study in advanced solid tumor cancers

Phase II trial planned for Cloretazine in elderly poor-risk AML patients

Locus and Lilly enter research agreement

FDA accepts IND for OxyQD

Enrollment completed in phase II stress urinary incontinence study of cizolirtine

U.S. launch for Avandaryl

Amitiza approved for chronic idiopathic constipation

GlaxoSmithKline's Arranon launched for the first time in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.